Colorectal Cancer PDX Models

Robust, well characterized preclinical models are essential for the advancement of targeted therapies for colorectal cancer. Patient-derived xenograft (PDX) models display a true representation of the human genetic and phenotypic heterogeneity seen in patient populations and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. CrownBio has one of the largest collections of colorectal cancer PDX models, including subcutaneous and orthotopic models to more closely recapitulate the tumor microenvironment. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
CR0004Colorectal CancerADCVIEW MODEL
CR0010Colorectal CancerADCVIEW MODEL
CR0012Colorectal CancerADCVIEW MODEL
CR0024Colorectal CancerADCVIEW MODEL
CR0028Colorectal CancerADCVIEW MODEL
CR0029Colorectal CancerADCVIEW MODEL
CR0047Colorectal CancerADCVIEW MODEL
CR0126Colorectal CancerMucinous adenocarcinomaVIEW MODEL
CR0133Colorectal CancerADCVIEW MODEL
CR0146Colorectal CancerADCVIEW MODEL